Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs NextMeds

Two GLP-1 desks, one scoreboard. We put ShedRx and NextMeds head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 227 · Grade C

NextMeds

Visit NextMeds Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 65 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make NextMeds a bad call — it's best for readers who want flat-price compounded semaglutide or tirzepatide bundled with a care coach and registered dietitian. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
25
Supply Reliability
86
67
Transparency
84
80
Access Breadth
85
90
Clinical Oversight
85
82
Track Record
86
62
ShedRxBrief Score 87 · 65NextMeds

Price, coverage & the tracker

ShedRxNextMeds
Brief Score87/100 (B+)65/100 (C)
Semaglutide$199/moFrom $129/mo (plus a separate fee, compounded)
Tirzepatide$299/moFrom $179/mo (plus a separate fee, compounded)
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

NextMeds: New to the tracker on 1 August 2026. The published line reads From $129/mo (plus a separate fee, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.